Click Therapeutics, a medical technology company, has announced the acquisition of assets from Better Therapeutics, aiming to enhance its development initiatives in cardiometabolic disease and obesity.
The acquisition includes a suite of digital therapeutic products, including AspyreRx (BT-001), the first Food and Drug Administration (FDA)-authorised prescription digital therapeutic for type 2 diabetes (T2D) and BT-004.
Recently, BT-004 received breakthrough device designation from the FDA to treat metabolic dysfunction-associated steatohepatitis (MASH).
The assets also encompass BT-002, to reduce blood pressure in patients with hypertension; and BT-003, designed to reduce LDL cholesterol in hyperlipidemia patients.
This move is expected to strengthen the portfolio of Click, particularly by advancing its pipeline in areas such as diabetes, obesity and cardiometabolic diseases, and complements its existing assets in psychiatry, central nervous system (CNS), and pain disorders.
The integration of Better Therapeutics’ intellectual property will not only expedite development timelines but also produce a digital therapy for chronic weight management.
This therapy is expected to be optimised for use alongside anti-obesity and diabetes medications, including GLP-1s, with both injectable and future oral formulations.
The digital therapeutic will leverage AspyreRx’s digital behavioural therapy, in conjunction with Click’s AI-enabled platform.
This platform utilises engagement techniques and digital mechanisms of action for treating the disease.
The integration of Better’s assets with Click’s platform is set to enable similar development opportunities in hypertension, T2D, hyperlipidemia, and MASH.
Click Therapeutics chief technology officer Han Chiu said: “Click can immediately strengthen AspyreRx by combining the latest engagement technology from our platform with Better’s therapeutic core. This allows us to efficiently deliver on the added clinical promise needed to support drug-software combination products with enhanced labels.
“We expect the resulting best-of-both programme will earn the long-term loyalty of patients, enabling superior outcomes and the generation of valuable real-world data insights for providers and payers.”
In March 2024, Better Therapeutics announced its intention to terminate its employees and explore alternatives, including the assignment for the benefit of creditors or a potential wind-down of the company.
It also declared a voluntary delisting of its securities from the Nasdaq Stock Market.
